{
    "clinical_study": {
        "@rank": "48437", 
        "acronym": "Rituxivac", 
        "arm_group": [
            {
                "arm_group_label": "Early group after rituximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients who received rituximab last dose 3-6 months before influenza vaccination will be the \"early group\"."
            }, 
            {
                "arm_group_label": "Late group after rituximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients who received rituximab last dose 9-12 months before influenza vaccination will be the \"late group\"."
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Active Comparator", 
                "description": "Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the number of responders to vaccination with the\n      influenza virus vaccine at different time points after last dose of rituximab in patients\n      with lymphoma. Secondly to study the immune-response to vaccination with influenza virus\n      vaccine, after treatment with rituximab in relation to the reconstitution of\n      immune-function."
        }, 
        "brief_title": "Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Non-Hodgkin Lymphoma (NHL)", 
        "condition_browse": {
            "mesh_term": [
                "Influenza, Human", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with non-Hodgkin's lymphoma, treated with rituximab (with a range of 6-12\n             cycles) and who are in remission.\n\n          2. Completion of rituximab therapy in the last twelve months before start of the study.\n\n          3. Age \u2265 18 years.\n\n          4. Signing of informed consent.\n\n        Exclusion Criteria:\n\n          1. Completion of rituximab therapy 7-8 months before start of the study.\n\n          2. Fever at time of vaccination.\n\n          3. Previous/known allergic reaction to any of the components of the vaccines given."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "98", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707628", 
            "org_study_id": "NL37320.100.11"
        }, 
        "intervention": {
            "arm_group_label": [
                "Early group after rituximab", 
                "Late group after rituximab", 
                "Control group"
            ], 
            "intervention_name": "influenza vaccination with influenza vaccine", 
            "intervention_type": "Biological", 
            "other_name": [
                "Influvac", 
                "Vaxigrip"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NHL", 
            "influenza vaccination", 
            "rituximab"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leeuwarden", 
                        "country": "Netherlands", 
                        "state": "Friesland"
                    }, 
                    "name": "Medisch Centrum Leeuwarden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "state": "Gelderland"
                    }, 
                    "name": "Canisius Wilhelmina Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "state": "Noord-Holland"
                    }, 
                    "name": "Onze Lieve Vrouwen Gasthuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands", 
                        "state": "Overrijssel"
                    }, 
                    "name": "Medisch Spectrum Twente"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands", 
                        "state": "Utrecht", 
                        "zip": "3435CM"
                    }, 
                    "name": "St. Antonius Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Delft", 
                        "country": "Netherlands", 
                        "state": "Zuid-Holland"
                    }, 
                    "name": "Reinier de Graaf Groep"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dordrecht", 
                        "country": "Netherlands", 
                        "state": "Zuid-Holland"
                    }, 
                    "name": "Albert Schweitzer Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "official_title": "Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab", 
        "overall_official": {
            "affiliation": "St. Antonius Hospital", 
            "last_name": "Minke AE Rab, Drs.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "The Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Influenza antibody titre", 
            "safety_issue": "No", 
            "time_frame": "3 weeks after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707628"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Antonius Hospital", 
            "investigator_full_name": "M. Rab", 
            "investigator_title": "Drs.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "number of memory B cells", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "lymphocyte subsets", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "immunoglobulin levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "IgG subclasses", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "production of IFN-\u03b3 by CD4+ cells", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Cytokines", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "genetic factors", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "St. Antonius Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Antonius Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}